NCT06506266View on ClinicalTrials.gov

Study of the Effect of HFA-152a and HFA-134a Propellants on Mucociliary Clearance in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

July 29, 2024

Primary Completion Date

October 24, 2024

Study Completion Date

October 24, 2024

Conditions
Asthma
Interventions
OTHER

HFA-152a

HFA-152a is administered via oral inhalation

OTHER

HFA-134a

HFA-134a is administered via oral inhalation

OTHER

Radiolabeled saline solution

Radiolabeled saline solution is administered via oral inhalation

Trial Locations (1)

NG11 6JS

GSK Investigational Site, Nottingham

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT06506266 - Study of the Effect of HFA-152a and HFA-134a Propellants on Mucociliary Clearance in Healthy Participants | Biotech Hunter | Biotech Hunter